STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma
Clinical trial NCT01653067 · UNKNOWN
Trial details
- NCT number
- NCT01653067
- Sponsor
- Mathias Witzens-Harig
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-09-01
- Primary completion
- 2018-06-01
- Enrollment
- 88
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.